Tenofovir-associated bone density loss
Iwen F Grigsby1,2,3,4,5, Lan Pham1,2,4, Louis M Mansky3,4,5, Raj Gopalakrishnan3,4, Kim C Mansky1,2,41Division of Orthodontics, 2Department of Developmental and Surgical Sciences, 3Department of Diagnostic and Biological Sciences, 4MinnCResT Program, School of Dentistry, and 5Institute for Molecular...
Main Authors: | Iwen F Grigsby, Lan Pham, Louis M Mansky, et al |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2009-12-01
|
Series: | Therapeutics and Clinical Risk Management |
Online Access: | http://www.dovepress.com/tenofovir-associated-bone-density-loss-a3880 |
Similar Items
-
Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
by: Hila Haskelberg, et al.
Published: (2012-01-01) -
No association between vitamin D deficiency and parathyroid hormone, bone density and bone turnover in a large cohort of HIV-infected men on tenofovir
by: Samarawickrama, A., et al.
Published: (2014) -
HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
by: Hila Haskelberg, et al.
Published: (2014-01-01) -
Bone mineral density loss in patients with cirrhosis
by: Mahmood Dhahir Al-Mendalawi
Published: (2019-01-01) -
Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings.
by: Andrea Ries Thurman, et al.
Published: (2019-01-01)